Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kurarinone for irritable bowel syndrome
ChiCTR2300071401Phase 4Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of kurarinone in irritable bowel syndrome (IBS) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: Clinical signs and symptoms of irritable bowel syndrome and Adverse reactions. Planned start May 2023; status: not yet recruiting.
02
Drugs
kurarinone
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on ChiCTR2300071401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071401.